| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
Enzaplatovir targets the respiratory syncytial virus (RSV) fusion (F) protein, which is essential for the virus to enter host cells. By inhibiting this fusion protein, enzaplatovir prevents the virus from fusing with the host cell membrane, thereby blocking viral entry and replication. Its mechanism of action is as a viral fusion protein inhibitor.
|
|---|---|
| ln Vitro |
Lower respiratory tract infections (LRTI) caused by the respiratory syncytial virus (RSV) are extremely costly to treat. A tiny chemical that inhibits RSV entrance is called enzaplatovir [1].
In vitro, enzaplatovir is a potent inhibitor of respiratory syncytial virus (RSV) replication. Its activity is assessed using in vitro antiviral assays, where cells are infected with RSV in the presence of varying concentrations of the compound. The inhibition of viral replication is measured by quantifying viral RNA or protein levels. |
| ln Vivo |
In vivo, enzaplatovir is an orally bioavailable inhibitor of RSV. Its oral bioavailability supports convenient administration in preclinical models and potential clinical use. It has shown activity against RSV infection in preclinical models.
|
| Enzyme Assay |
Non-cellular assays for enzaplatovir are not standard, as it is a viral entry inhibitor whose activity is typically assessed in cell-based assays. Its binding to the RSV fusion protein can be studied using surface plasmon resonance (SPR) or other biophysical methods. The compound's ability to inhibit fusion can be assessed in cell-free fusion assays using liposomes or synthetic membranes.
|
| Cell Assay |
In vitro cellular assays for enzaplatovir involve treating RSV-infected cells with the compound and measuring viral replication. Cells are infected with RSV and then treated with varying concentrations of enzaplatovir. After incubation, viral RNA is quantified by qRT-PCR, or viral protein expression is measured by immunofluorescence or Western blotting. The EC₅₀ for inhibition of viral replication is determined from the dose-response curves.
|
| Animal Protocol |
In vivo animal experiments with enzaplatovir are conducted in rodent models of RSV infection. Animals are infected with RSV via intranasal administration and then treated with enzaplatovir via oral gavage. Viral load in the lungs is measured by plaque assay or qRT-PCR. The compound's ability to reduce viral load and improve clinical outcomes is assessed.
|
| ADME/Pharmacokinetics |
Enzaplatovir has a molecular weight of 377.40 and a molecular formula of C₂₀H₁₉N₅O₃. It is a solid powder with a purity of 99.98%. The compound is typically stored in a cool, dry place. It is soluble in DMSO.
|
| Toxicity/Toxicokinetics |
Enzaplatovir is a research compound for laboratory use only and is not approved for human therapeutic use. In preclinical studies, it has been generally well-tolerated at therapeutic doses. Standard laboratory safety precautions should be followed when handling the compound. It may cause skin, eye, and respiratory irritation. Appropriate personal protective equipment should be used.
|
| References | |
| Additional Infomation |
Enzaplatovir (BTA-C585; CAS 1323077-89-9) is a novel, orally bioavailable inhibitor of the respiratory syncytial virus (RSV) fusion protein. It functions as a viral fusion protein inhibitor and has been developed for the treatment of RSV infections. It is available from various commercial suppliers for research applications.
|
| Molecular Formula |
C20H19N5O3
|
|---|---|
| Molecular Weight |
377.404
|
| Exact Mass |
377.148
|
| CAS # |
1323077-89-9
|
| PubChem CID |
58406357
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
663.0±55.0 °C at 760 mmHg
|
| Flash Point |
354.8±31.5 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.731
|
| LogP |
-0.43
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
28
|
| Complexity |
660
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC1=NC=C(C=C1)[C@]23CN4C=CC=C4C(=O)N2CCN3C(=O)C5=CON=C5C
|
| InChi Key |
KUDXTBCRESIJFH-FQEVSTJZSA-N
|
| InChi Code |
InChI=1S/C20H19N5O3/c1-13-5-6-15(10-21-13)20-12-23-7-3-4-17(23)19(27)25(20)9-8-24(20)18(26)16-11-28-22-14(16)2/h3-7,10-11H,8-9,12H2,1-2H3/t20-/m0/s1
|
| Chemical Name |
(3R)-4-(3-methyl-1,2-oxazole-4-carbonyl)-3-(6-methylpyridin-3-yl)-1,4,7-triazatricyclo[7.3.0.03,7]dodeca-9,11-dien-8-one
|
| Synonyms |
BTA585 BTA-585 Enzaplatovir
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~200 mg/mL (~529.94 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 6 mg/mL (15.90 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 60.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (13.25 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5 mg/mL (13.25 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6497 mL | 13.2485 mL | 26.4971 mL | |
| 5 mM | 0.5299 mL | 2.6497 mL | 5.2994 mL | |
| 10 mM | 0.2650 mL | 1.3249 mL | 2.6497 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
